Volume 99, Issue 6 p. 1415-1420

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy

Hansjörg Vees

Corresponding Author

Hansjörg Vees

Service of Radiation Oncology,

Hansjörg Vees, Division de Radio-oncologie, Hôpitaux Universitaires, 1211 Genève 14, Switzerland.
e-mail: [email protected]Search for more papers by this author
Franz Buchegger

Franz Buchegger

Service of Nuclear Medicine and

Search for more papers by this author
Susanne Albrecht

Susanne Albrecht

Service of Nuclear Medicine and

Search for more papers by this author
Haleem Khan

Haleem Khan

Institute of Radiology Jean Violette, Geneva, Switzerland, and

Search for more papers by this author
Daniela Husarik

Daniela Husarik

Department of Nuclear Medicine, University Hospital, Geneva,

Search for more papers by this author
Habib Zaidi

Habib Zaidi

Service of Nuclear Medicine and

Search for more papers by this author
Dmitri Soloviev

Dmitri Soloviev

Service of Nuclear Medicine and

Search for more papers by this author
Thomas F. Hany

Thomas F. Hany

Department of Nuclear Medicine, University Hospital, Geneva,

Search for more papers by this author
Raymond Miralbell

Raymond Miralbell

Service of Radiation Oncology,

Servei de Radio-oncologia, Instituto Oncológico Teknon, Barcelona, Spain

Search for more papers by this author
First published: 08 April 2007
Citations: 171

Abstract

OBJECTIVES

To assess the value of positron emission tomography (PET)/computed tomography (CT) with either 18F-choline and/or 11C-acetate, of residual or recurrent tumour after radical prostatectomy (RP) in patients with a prostate-specific antigen (PSA) level of <1 ng/mL and referred for adjuvant or salvage radiotherapy.

PATIENTS AND METHODS

In all, 22 PET/CT studies were performed, 11 with 18F-choline (group A) and 11 with 11C-acetate (group B), in 20 consecutive patients (two undergoing PET/CT scans with both tracers). The median (range) PSA level before PET/CT was 0.33 (0.08–0.76) ng/mL. Endorectal-coil magnetic resonance imaging (MRI) was used in 18 patients. Nineteen patients were eligible for evaluation of biochemical response after salvage radiotherapy.

RESULTS

There was abnormal local tracer uptake in five and six patients in group A and B, respectively. Except for a single positive obturator lymph node, there was no other site of metastasis. In the two patients evaluated with both tracers there was no pathological uptake. Endorectal MRI was locally positive in 15 of 18 patients; 12 of 19 responded with a marked decrease in PSA level (half or more from baseline) 6 months after salvage radiotherapy.

CONCLUSIONS

Although 18F-choline and 11C-acetate PET/CT studies succeeded in detecting local residual or recurrent disease in about half the patients with PSA levels of <1 ng/mL after RP, these studies cannot yet be recommended as a standard diagnostic tool for early relapse or suspicion of subclinical minimally persistent disease after surgery. Endorectal MRI might be more helpful, especially in patients with a low likelihood of distant metastases. Nevertheless, further research with 18F-choline and/or 11C-acetate PET with optimal spatial resolution might be needed for patients with a high risk of distant relapse after RP even at low PSA values.